Hillstar Bio
Boston, Massachusetts, United States · Biotechnology, Health Care, Therapeutics · 17 employees
Hillstar Bio is a biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases. Their approach selectively targets and depletes pathogenic immune cells while preserving healthy ones, aiming to provide durable relief and improve patient outcomes. The company's innovative methods leverage tailored discovery techniques, distinguishing them from tr
Funding history
- Series series a — $67.0M — Mar 2025
Recent signals
- May 28, 2025: Hillstar Bio Appoints Maude Tessier as Chief Operating Officer
- Mar 25, 2025: Raised $67.0M in Series series a
See plans & pricing → Track Hillstar Bio’s funding, hiring, and signals — with verified contacts — on Fundz.